Abstract:Docetaxel, frequently used for the treatment of breast cancer, is mainly metabolized via hepatic cytochrome P450 (CYP) 3A in humans and is also a substrate of P-glycoprotein (P-gp). Wogonin has been shown to be able to modulate the activities of CYPs and P-gp, and it could serve as an adjuvant chemotherapeutic agent. However, the impacts of co-administration of wogonin and docetaxel on their pharmacokinetics have not been studied because of a lack of an analytical method for their simultaneous measurement. In the present study, we established an HPLC-MS/MS method for simultaneous measurement of wogonin and docetaxel in rat plasma, and it was then utilized to explore the pharmacokinetics of wogonin and the herb-drug interactions between wogonin and docetaxel after their combined administration in rats with mammary tumors. The rats received 10, 20 and 40 mg/kg wogonin via oral administration, with or without docetaxel intravenously administered at 10 mg/kg, and the plasma concentrations of wogonin and docetaxel were measured using the established and validated HPLC-MS/MS method. The Cmax and AUC0-t of wogonin were proportionally increased in the dose range from 10 to 40 mg/kg, suggesting a linear pharmacokinetics of wogonin. Moreover, the Cmax and AUC0-t of docetaxel and the AUC0-t of wogonin were increased after co-administration (p < 0.05), indicating increased in vivo exposures of both wogonin and docetaxel, which might lead to an increase in not only therapeutic but also toxic effects. Thus the alterations of pharmacokinetics should be taken into consideration when wogonin and docetaxel are co-administered.

In Vivo Pharmacokinetics and Tissue Distribution of Wogonin Albumin Microspheres in Rats

Wogonin Pharmacokinetic Behavior in Rats after Intravenous Injection

Pharmacokinetics, tissue distribution, excretion and plasma protein binding studies of wogonin in rats.

Preparation of Wogonin Liposomes and Its Pharmacokinetics in Rats

Pharmacokinetics and Tissue Distribution of Silybin Gelatin Microspheres in Vivo in Rats

Mechanism in the existent difference in form of wogonin/wogonoside between plasma and intestine/liver in rats

Metabolite Identification and the Development of a Simultaneous Quantification Method for Wogonin and Wogonin-7-o-glucuronide: Application to a Distribution Study in Mice Liver

Determination of GL-V9, a Derivative of Wogonin, in Rat Plasma by UPLC-MS/MS and Its Application to a Pharmacokinetic Study after Oral and Pulmonary Administration.

Mechanistic Study of Absorption and First-Pass Metabolism of GL-V9, a Derivative of Wogonin

Wogonin Accelerates Hematoma Clearance and Improves Neurological Outcome Via the PPAR-γ Pathway after Intracerebral Hemorrhage

SPE and LC for Analysis of the Tissue Distribution of Wogonin and Its Metabolite in Tumor-Bearing Nude Mice

Subchronic toxicity and plasma pharmacokinetic studies on wogonin, a natural flavonoid, in Beagle dogs.

Development of A New Hplc Method for Wogonin in Rat Plasma: Compatibility of Standard and Test Samples

Identification and quantification of baicalein, wogonin, oroxylin A and their major glucuronide conjugated metabolites in rat plasma after oral administration of Radix scutellariae product.

Pharmacokinetic Study and Tissue Distribution of Single Mangiferin after Intravenous Administration in Rats

High-Performance Liquid Chromatographic Method for the Determination and Pharmacokinetic Study of Wogonoside in Rat Serum after Oral Administration of Traditional Chinese Medicinal Preparation Huang-Lian-Jie-Du Decoction

Pharmacokinetic Properties of Wogonin and Its Herb-Drug Interactions with Docetaxel in Rats with Mammary Tumors.

Inhibitory Effects of Wogonin on Catalytic Activity of Cytochrome P450 Enzyme in Human Liver Microsomes

Pharmacokinetics and Tissue Distribution Study of Gambogic Acid and Gambogic Acid Nanosuspension in Mice by UHPLC-MS/MS

Effect of wogonin on the viability,migration and invasion of hepatoma cell line SMMC-7721

Resveratrol Loaded Glycyrrhizic Acid-Conjugated Human Serum Albumin Nanoparticles For Tail Vein Injection Ii: Pharmacokinetics, Tissue Distribution And Bioavailability